<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03397238</url>
  </required_header>
  <id_info>
    <org_study_id>NL62671.091.17</org_study_id>
    <secondary_id>2017-3628</secondary_id>
    <nct_id>NCT03397238</nct_id>
  </id_info>
  <brief_title>Myeloid Cell Reprogramming in Thyroid Carcinoma</brief_title>
  <official_title>Myeloid Cell Reprogramming in the Context of Radioiodine Therapy in Patients With Non-Medullary Thyroid Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the reprogramming of myeloid cells in patients with thyroid&#xD;
      carcinoma. The investigators hypothesize that tumor-derived factors change the function of&#xD;
      myeloid cells in such a way that these immune cells promote tumor growth rather than combat&#xD;
      the tumor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 6, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">November 26, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Transcriptional reprogramming of myeloid cells</measure>
    <time_frame>baseline</time_frame>
    <description>RNAseq</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Epigenetic reprogramming of myeloid cells</measure>
    <time_frame>baseline</time_frame>
    <description>ATAC-seq</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional reprogramming of myeloid cells</measure>
    <time_frame>baseline</time_frame>
    <description>Cytokine response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolites</measure>
    <time_frame>baseline</time_frame>
    <description>Presence and level metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of reprogramming after RAI treatment</measure>
    <time_frame>baseline and 7 days after RAI treatment</time_frame>
    <description>RNAseq</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">41</enrollment>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Non-metastatic TC</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Metastatic TC</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>MNG surgery</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>MNG RAI treatment</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Group 1:&#xD;
&#xD;
        Subject is newly diagnosed with TC, therapy-naive and is planned to receive conventional&#xD;
        treatment by surgery followed by RAI; no evidence of local or distant metastases&#xD;
&#xD;
          -  Group 2:&#xD;
&#xD;
        Subject has TC with evidence of distant metastases (either newly diagnosed or therapy-naive&#xD;
        or patients with persistent or recurrent disease); at least 4 months since the previous&#xD;
        treatment with RAI if applicable&#xD;
&#xD;
          -  Group 3:&#xD;
&#xD;
        Subject is diagnosed with MNG, is euthyroid, and is planned to undergo surgery - Group 4:&#xD;
        Subject is diagnosed with MNG, is euthyroid, and is planned to receive RAI treatment&#xD;
&#xD;
        - Group 5: Healthy individuals who are euthyroid and have no evidence of thyroid disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mentally incompetent&#xD;
&#xD;
          -  Pregnant, trying to become pregnant or breastfeeding&#xD;
&#xD;
          -  Known inflammatory or infectious diseases or an immunosuppressive status&#xD;
&#xD;
          -  Using medication interfering with the immune system&#xD;
&#xD;
          -  Reduced platelet counts or other conditions associated with an increased risk of&#xD;
             bleeding&#xD;
&#xD;
          -  Severe comorbidities: other active malignancy (except for basal cell carcinoma)&#xD;
&#xD;
          -  Serious psychiatric pathology&#xD;
&#xD;
          -  A self-reported alcohol consumption of &gt;21 units per week&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 18, 2017</study_first_submitted>
  <study_first_submitted_qc>January 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2018</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myeloid cell</keyword>
  <keyword>reprogramming</keyword>
  <keyword>monocyte</keyword>
  <keyword>tumor-associated macrophage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

